Join Nusano for a virtual KOL panel discussion led by Suji Jeong, PhD (Founding Partner, The SJR Group), featuring Phil Nicklin (Senior Analyst, LifeSci Consulting), Dr. Ashley Mishoe, PharmD (Vice President of Regulatory Affairs and Quality Assurance, PharmaLogic), and Dr. Johnnie José Orozco, MD, PhD (Associate Professor, Translational Science and Therapeutics Division, Fred Hutch Cancer Center), who will discuss emerging trends in the radiotherapeutics landscape and the $30 billion potential radioisotopes market projected in the next five years that is capturing the attention of investors and companies.

The event will highlight the therapeutic potential of isotopes on the horizon beyond Lutetium-177 and Actinium-225, as well as supply chain complexities, the role of CDMOs in bringing radiotherapeutics to patients, and the optimal timing for commercial-scale product development.

Nusano’s production platform enables the creation of rare and hard-to-produce medical radioisotopes in quantities needed for commercial-stage diagnostics and therapeutics. A reliable supply of radioisotopes is an important requirement for drugmakers developing and manufacturing next-generation pharmaceuticals needed to advance the fight against cancer.

A live question and answer session will follow the formal presentations.